Sorafenib Patent Search and China Sorafenib Market 2010-2019 Size Reviewed in New Research Reports

Jul 14, 2015, 02:00 ET from RnR Market Research

DALLAS, July 14, 2015 /PRNewswire/ --

RnRMarketResearch.com adds Investigation Report on China Sorafenib Market, 2010-2019 and Sorafenib - Comprehensive patent search 2015 research reports to its collection of market intelligence on cancer drugs.

Complete report on China sorafenib market spread across 20 pages, talking about Bayer Pharma AG (Nexavar) and supported with 13 charts is now available at http://www.rnrmarketresearch.com/investigation-report-on-china-sorafenib-market-2010-2019-market-report.html .

According to this new, 2015 investigation report on China sorafenib market, incidences of liver cancer and kidney cancer in China are growing gradually. The Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version) says kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.

According to a China sorafenib market survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year. With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%. Order a copy of Investigation Report on China Sorafenib Market, 2010-2019 at http://www.rnrmarketresearch.com/contacts/purchase?rname=394994 .

Readers can get at least the following information from this China sorafenib market report: market size of sorafenib in China, major manufacturers of sorafenib in Chinese market, retail price of sorafenib in China and market outlook of sorafenib in China. The publishers suggest manufacturers of anti-tumor drugs, investors/ research institutions interested in Chinese medicine market and anyone with any interest in the medicine market, please contact CRI for customized survey service to purchase this research report.

The Sorafenib - Comprehensive patent search report contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. This report covers data and information on : International Nonproprietary Name: Sorafenib; Indications: Advanced renal cell carcinoma; unresectable hepatocellular carcinoma and Innovator: Bayer (Nexavar). The research quickly grasps complexity and helps readers in identifying patents covering molecule, formulation, process, use, combinations and more. Grouped by patent family and assigned to development categories based on interpretation of key aspects of the patent claims, this information also provides manual filtration of patents so you only see what is relevant to you. It covers the world's major territories with equivalents in over 80 countries that never let you miss a change in the patent landscape. Get monthly updates to patent families, statuses, and litigation clearly identified with comprehensive litigation alerts linked to patent numbers while being able to add your own notes, save searches and results. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, these in-depth patent search reports are the benchmark in comprehensive, accurate and relevant patent data. Searched and analyzed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data. Complete report on Sorafenib - Comprehensive patent search is available at http://www.rnrmarketresearch.com/sorafenib-comprehensive-patent-search-market-report.html .

On a related note, a third research titled Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation identified substantial variation in the alignment of first-in-class products to underlying dysfunctional signaling at protein and genetic level. The first-in-class products were compared in an in-depth analysis using various parameters to measure the potential of each target, with the most promising targets being further substantiated by published clinical and scientific evidence. Results of the analysis suggested that first-in-class status is not a feature that, in its own right, will create a successful product. However, there are a large number of first-in-class products backed by clinical and Preclinical data that are exciting future prospects for the liver cancer market. The report features an analysis of granted patent applications in the liver cancer market, which was used as an indication of innovation at the earliest stage of product development. Patent analysis provides an insight into the pre-developmental landscape, and identifies long-term future trends within a disease market. In liver cancer, the trend in patent applications in terms of predominant molecular targets reflects the pipeline landscape, suggesting that liver cancer therapeutics will continue to target key oncogenic signaling pathways in the long term. The frequency at which companies apply for patents within the market helps to identify companies that are trying to establish themselves or increase their liver cancer market share. This information identifies not only potential competitors, but also companies that may seek strategic partnerships to enter drug development. Read more at http://www.rnrmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market-report.html .

Explore more reports on the cancer drugs market as well as cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+/Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS/Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com


SOURCE RnR Market Research